Sugi Predict

Sugi Predict / Compounds / SCHEMBL1145076

SCHEMBL1145076

SCHEMBL1145076

Cc1n[nH]c2ccc(C(=O)O)cc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP2K4 P45985 7/20 0.57
▸ MAPK1 P28482 6/20 0.57
▸ MAPK6 Q16659 5/20 0.57
▸ MAPKAPK3 Q16644 4/20 0.57
▸ KDM4E B2RXH2 2/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ THRB P10828 1/20 0.54
▸ HPGD P15428 1/20 0.54
▸ TDP1 Q9NUW8 3/20 0.46
▸ MAPKAPK2 P49137 1/20 0.46
▸ MAPKAPK5 Q8IW41 1/20 0.46
▸ DYRK1A Q13627 1/20 0.46
▸ MEN1 O00255 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ HSP90AA1 P07900 1/20 0.45
▸ ESR2 Q92731 1/20 0.45
▸ ITK Q08881 1/20 0.45
▸ JAK2 O60674 1/20 0.44
▸ JAK1 P23458 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31504557 1.00 MAP2K4 (0.57) MAP2K4MAPK1MAPK6MAPKAPK3KDM4E
SCHEMBL16308650 0.86 KIF11 (0.50) MAP2K4MAPK1MAPK6MAPKAPK3KDM4E
SCHEMBL1144879 0.86 DYRK1A (0.52) MAP2K4MAPK1MAPK6MAPKAPK3KDM4E
SCHEMBL31746650 0.86 DYRK1A (0.52) MAP2K4MAPK1MAPK6MAPKAPK3KDM4E
SCHEMBL23559721 0.85 MAP2K4 (0.58) MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2
SCHEMBL21509969 0.84 MAP2K4 (0.60) MAP2K4MAPK1MAPK6MAPKAPK3LMNA
SCHEMBL6618549 0.82 ADORA2A (0.43) MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2
SCHEMBL14872686 0.82 MAPK1 (0.65) MAP2K4MAPK1MAPK6MAPKAPK3MAPK3
SCHEMBL1501529 0.82 KDM4E (0.55) MAP2K4KDM4EALDH1A1HPGDDYRK1A
SCHEMBL4403122 0.82 MAPK1 (0.43) MAP2K4MAPK1MAPK6MAPKAPK3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250313574-A1 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME EISAI R&D MANAGEMENT CO., LTD. (JP) 2025-10-09 — — US disclosed
US-20230271949-A1 GLP-1R MODULATING COMPOUNDS ASCLETIS BIOSCIENCE CO., LTD. (CN) 2023-08-31 — — US disclosed
WO-2023164358-A1 GLP-1R MODULATING COMPOUNDS ASCLETIS BIOSCIENCE CO., LTD. (CN) 2023-08-31 — — WO disclosed
WO-2023078337-A1 CDK8/19 DUAL INHIBITORS AND METHODS OF USE INSILICO MEDICINE IP LIMITED (CN) 2023-05-11 — — WO disclosed
WO-2023078337-A1 CDK8/19 DUAL INHIBITORS AND METHODS OF USE INSILICO MEDICINE IP LIMITED (CN) 2023-05-11 — — WO disclosed
CN-107849044-B Triaza-spirodecanones as DDR1 inhibitors 豪夫迈·罗氏有限公司 2021-06-25 — — CN disclosed
US-10953012-B2 Heterocyclic compounds for the inhibition of pask BIOENERGENIX LLC (US) 2021-03-23 — — US disclosed
US-10953012-B2 Heterocyclic compounds for the inhibition of pask BIOENERGENIX LLC (US) 2021-03-23 — — US disclosed
EP-3317279-B1 TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS HOFFMANN LA ROCHE (CH) 2021-01-27 — — EP disclosed
US-10858321-B2 Composition for inducing cell reprogramming GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2020-12-08 — — US disclosed
US-20080255145-A1 Thiadiazole compounds and methods of use AMGEN INC. (US) 2008-10-16 — — US disclosed
US-20080255145-A1 Thiadiazole compounds and methods of use AMGEN INC. (US) 2008-10-16 — — US disclosed
US-20080255145-A1 Thiadiazole compounds and methods of use AMGEN INC. (US) 2008-10-16 — — US disclosed
US-20080242694-A1 Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith D SIDOCKY NEIL R 2008-10-02 — — US disclosed
US-7354944-B2 Thiadiazole compounds and methods of use AMGEN INC. (US) 2008-04-08 — — US disclosed
US-7354944-B2 Thiadiazole compounds and methods of use AMGEN INC. (US) 2008-04-08 — — US disclosed
US-7354944-B2 Thiadiazole compounds and methods of use AMGEN INC. (US) 2008-04-08 — — US disclosed
EP-1809282-A2 THIADIAZOLE COMPOUNDS AND METHODS OF USE Amgen, Inc (US) 2007-07-25 — — EP disclosed
US-20060154961-A1 Thiadiazole compounds and methods of use AMGEN INC. 2006-07-13 — — US disclosed
WO-2006044860-A2 THIADIAZOLE COMPOUNDS AND METHODS OF USE AMGEN, INC. (US) 2006-04-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255145-A1 Thiadiazole compounds and methods of use PDK2, PDK1, PANK2 MAP2K4 468/4885MAPK1 264/4885MAPK6 218/4885
US-10858321-B2 Composition for inducing cell reprogramming MCL1, IRF3, STING1 MAP2K4 2990/4885MAPK1 2019/4885MAPK6 2379/4885
US-20230271949-A1 GLP-1R MODULATING COMPOUNDS GLP1R, GIPR, GPR119 MAP2K4 2115/4885MAPK1 1172/4885MAPK6 1022/4885
US-20250313574-A1 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME NEU1, NEU2, NEU4 MAP2K4 4617/4885MAPK1 3114/4885MAPK6 2750/4885
US-20080242694-A1 Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith JAK2, CHEK2, MTOR MAP2K4 1105/4885MAPK1 115/4885MAPK6 136/4885
US-10953012-B2 Heterocyclic compounds for the inhibition of pask PASK, PDXK, PANK2 MAP2K4 476/4885MAPK1 574/4885MAPK6 439/4885
US-20060154961-A1 Thiadiazole compounds and methods of use PDK2, PDK1, PANK2 MAP2K4 468/4885MAPK1 264/4885MAPK6 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.